TerminatedInterventionalPhase 3Updated Jun 30, 2022
GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis | NCT01451905 | Trialant
Unknown statusInterventionalNot ApplicableUpdated Jun 21, 2012
GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis
ClinicalTrials.gov ID
NCT01451905
Lead Sponsor
University Hospital, Gentofte, CopenhagenOTHER
Overall Status
Unknown status
Study Type
Interventional
Phase
Not Applicable
Enrollment
12Estimated
Last Update Posted
Jun 21, 2012Estimated
Start Date
Aug 2011
Primary Completion Date
Dec 2012Estimated
Completion Date
Dec 2012Estimated
Brief Summary
To examine GLP-1 receptors in skin of psoriasis patients compared with the skin of humans with no skin disease
Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI
Liraglutide
Placebo
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
4.3 Inclusion Criteria
Caucasians above 18 years of age
Plaque psoriasis
PASI score >10
No treatment or stable treatment of psoriasis during at least 3 months before inclusion
Steady weight through 3 months with a body mass index (BMI) above 27 kg/m2
Normal blood pressure
Spiral or hormonal birth control for fertile women during the entire treatment period and at least 3 days after the end of the treatment period (~5 times the plasma half-life) 4.4 Exclusion Criteria
Psoriasis arthritis
Fasting plasma glucose > 7.5 mmol/L or HbA1c > 7.5%
Type 1 diabetes
Treatment for type 2 diabetes with GLP-1-based medicine (DDP-4-inhibitors or GLP-1-receptor-agonists)
Heart failure, NYHA class III-IV
Uraemia, end-stage renal disease, or any other cause of impaired renal function with s-creatinine >150 µM and/or albuminuria
Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase (ASAT) >2 x upper normal serum levels)